The discovery of novel MSLN dual-targeted drugs that could mimic the deletion of host MSLN expression, such as antibody-conjugates [55,56] and vaccines [57,58], and be cytotoxic to tumor cells would be ideal to improve survival in OvCa and other cancers with MSLN overexpression. This evidence concerns the gene MSLN and cancer.